Full-Time
Develops therapies for autoimmune diseases
No salary listed
Senior, Expert
Belmont, MA, USA
This is an on-site position based in the Watertown, MA office and the employee will be required to work in the office on a regular basis.
Upload your resume to see how it matches 2 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy is currently in the IND enabling studies phase and is expected to enter clinical trials by 2025. Abata stands out in the biotech market by targeting a specific group of patients and forming strategic partnerships, such as with ElevateBio, to enhance their research and manufacturing capabilities. The company's goal is to improve patient outcomes through advanced treatments while fostering a collaborative work environment.
Company Size
11-50
Company Stage
Early VC
Total Funding
$190M
Headquarters
Cambridge, Massachusetts
Founded
2021
Help us improve and share your feedback! Did you find this helpful?
WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) - Abata Therapeutics, a clinical-stage biotech company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory diseases, today announced the appointment of Joanne Beck, Ph.D., as chief technical officer.
WATERTOWN, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) — Abata Therapeutics, a company focused on transforming lives with Treg therapies for... Read More
Founded by pioneers in Treg biology, TCR and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers, Abata has developed a differentiated product engine to create engineered Treg cell therapies that are tissue-specific, robust, and durable.
Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases, today announced the appointment of Leonard "Lenny" Dragone, M.D., Ph.D., as its new chief medical officer.
Abata has collaborated with ElevateBio BaseCamp to develop a manufacturing process that engineers and grows Tregs for therapeutic use.